The Phase 3 study NCT06244758, investigating finerenone for its effects on renal oxidative stress in patients with Type 2 diabetes, reached its primary completion on 2025-11-25. This trial enrolled 91 participants to evaluate the drug's impact on renal vasculature and hemodynamics.
Background
Finerenone is being investigated for its potential to impact renal oxidative stress and hemodynamics. This study specifically focuses on patients with Type 2 diabetes, a condition often associated with kidney complications.
Trial design
The study NCT06244758, titled "Finerenone and Renal Oxidative Stress," is a Phase 3, prospective, double-blind, placebo-controlled, randomized mechanistic study. It enrolled 91 participants diagnosed with Type 2 diabetes. Participants were randomized to receive either finerenone 20 mg oral tablet or placebo. The trial's primary objective is to analyze the impact of finerenone on the oxidative stress level of renal vasculature, along with detailed analysis of renal hemodynamics parameters such as renal plasma flow, total renal vascular resistance, and filtration fraction, and changes in renal nitric oxide activity.
What this means
The primary completion of this Phase 3 study marks a significant milestone in the investigation of finerenone for its effects on renal oxidative stress in patients with Type 2 diabetes. The data collected from the 91 participants will now undergo analysis to determine the impact of finerenone on renal vasculature, hemodynamics, and nitric oxide activity as per the study's objectives. Future reporting of these results will provide insights into the drug's potential role in managing kidney-related complications in this patient population.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT06244758, titled "Finerenone and Renal Oxidative Stress," indicates primary completion on 2025-11-25, and is available on clinicaltrials.gov.